Table 2.

Participant demographics

Demographic variable	Insomnia: mean (M), SD and/or no reporting	No insomnia: mean (M), SD and/or no reporting	Significance test for group differences
Age	M=42.70, SD=16.30 (range=23–67 years)	M=48.00, SD=15.58 (range=29–73 years)	t(18)=0.74, p=0.47
Sex	9 female, 1 male	2 female, 8 male	Fisher’s exact p=0.002
Race/ethnicity	10 white non-Hispanic	10 white non-Hispanic	Fisher’s exact p=1.0
IBD type and location	7 Crohn’s disease Location 3 ileal only 2 ileocolonic 1 colonic only 1 upper tract, colonic Phenotype 3 inflammatory 3 stricturing 1 penetrating Perianal Involvement 3 yes 4 no 3 ulcerative colitis 3 left sided disease	5 Crohn’s disease 3 ileal only 1 ileocolonic 1 colonic only Phenotype 1 inflammatory 3 stricturing 1 penetrating Perianal Involvement 2 yes 3 no 5 ulcerative colitis 3 left sided 2 extensive colitis	Fisher’s exact for Crohn’s vs UC p=0.65
Years since IBD diagnosis	M=14.50, SD=12.87 (range=1–44 years)	M=11.80, SD=9.39 (range=2–30 years)	t(18)=-.56, p=0.58
IBD medications*	9 taking: 3 infliximab alone 2 vedolizumab alone 1 ustekinumab alone 1 ustekinumab+prednisone 1 adalimumab +prednisone 1 mesalamine alone	10 taking: 2 adalimumab alone 1 adalimumab +azathioprine 1 infliximab alone alone 1 infliximab+prednisone 1 ustekinumab+prednisone 1 vedolizumab alone 1 mesalamine alone 1 mesalamine +methotrexate 1 sulfasalazine alone	Fisher’s exact p=1.0
Psychiatric medications (including sleep medications and hypnotics)*	3 taking: 2 antidepressants 1 antidepressant, anticonvulsant and atypical antipsychotic	0 taking	Fisher’s exact p=0.21
Disease status (remission vs active) based on PRO-3	4 in remission 6 active disease	5 in remission 5 active disease	X2 (1, N=20)=0.20, p=0.65

Bolded values are significant though should be interpreted with caution given our small sample size.

*Dose did not change over the course of the trial.

IBD, inflammatory bowel disease; PRO-3, patient-reported outcome-3; UC, ulcerative colitis.